Cargando…
Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
The covalent inhibitor of Bruton’s tyrosine kinase ibrutinib and the specific Bcl-2 inhibitor venetoclax are both highly efficacious single-agent drugs in the treatment of chronic lymphocytic leukemia (CLL). Based on their complementary modes of action, ibrutinib and venetoclax are hypothesized to a...
Autores principales: | Kater, Arnon P., Slinger, Erik, Cretenet, Gaspard, Martens, Anne W., Balasubramanian, Sriram, Leverson, Joel D., Eldering, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153000/ https://www.ncbi.nlm.nih.gov/pubmed/34555843 http://dx.doi.org/10.1182/bloodadvances.2021004861 |
Ejemplares similares
-
P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Montironi, Chiara, et al.
Publicado: (2023) -
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
por: Chua, Chong Chyn, et al.
Publicado: (2022) -
P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Simon-Molas, Helga, et al.
Publicado: (2023) -
T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
por: Montironi, Chiara, et al.
Publicado: (2023) -
S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)